Le Lézard
Classified in: Health
Subject: TRADE SHOWS/SEMINARS/WEBINARS

Solis Tek to Present at Annual Cannabis World Congress & Business Expo


CARSON, CA--(Marketwired - September 07, 2017) - Solis Tek (OTCQB: SLTK), a vertically integrated technology innovator, developer, manufacturer and distributor focused on bringing products and solutions to commercial cannabis growers in legal markets across the U.S., announced today that Alan Lien, Co-Founder, Chairman and President of Solis Tek, will be presenting on "The Effects of Light Science on Plant Biology" at the Cannabis World Congress & Business Expo.

The presentation will take place on Thursday, September 14, 2017 at 11:00-11:40 a.m. in Room 502B.

Dennis G. Forchic, Chief Executive Officer of Solis Tek, and Mr. Lien will also be hosting a presentation on the Company at the Showcase Theater on Thursday, September 14, at 4:40 p.m.-5:00 pm and on Friday, September 15, at 2:40 p.m.-3:00 pm. The Expo will be held September 13-15, 2017 at the Los Angeles Convention Center, 1201 South Figueroa St., Los Angeles, CA 90015. Solis Tek will also have a booth in the expo hall -- Booth #115.

Mr. Lien said, "Solis Tek is a leading producer of lighting solutions and accessories to help cannabis growers achieve higher yields. During the conference, I will explain how using scientifically verified lighting products can transform a cultivation facility, increasing both product quality and yield. I will also host a presentation alongside Dennis G. Forchic, CEO, about Solis Tek's business model and growth path for interested investors."

Speaker Presentation Room 502B:
"The Effects of Light Science on Plant Biology"
Alan Lien, Co-Founder, Chairman and President of Solis Tek
Thursday, September 14, 2017 from 11:00 a.m.-11:40 a.m.

Solis Tek Presentation at the Showcase Theatre:
Dennis G. Forchic, Chief Executive Officer of Solis Tek and Alan Lien, Co-Founder, Chairman and President of Solis Tek
September 14, 2017 at 4:40 p.m. and September 15, 2017 at 2:40 p.m.

About Solis Tek
Solis Tek is a vertically integrated technology innovator, developer, manufacturer and distributor focused on bringing products and solutions to commercial cannabis growers in both the medical and recreational space in legal markets across the U.S. For nearly a decade, growers have used Solis Tek's lighting solutions to increase yield, lower costs and grow better to maximize their return on investment. The Company's customers include retail stores, distributors and commercial growers in the United States and abroad. For more information, please visit our website, www.solis-tek.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


These press releases may also interest you

at 01:00
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...

at 00:00
Spectrum Dynamic's customers will...

28 avr 2024
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...



News published on and distributed by: